| 2025年中报 | 2024年年报 | 2024年中报 | 2023年年报 | 2023年中报 | |
|---|---|---|---|---|---|
| 营业收入(元) | |||||
| MAH01(元) | - | - | - | 124,965,278.48 | 54,670,320.40 |
| MAH02(元) | - | - | - | 76,082,079.58 | 49,219,247.73 |
| CDMO及其他(元) | - | - | - | 149,829,358.74 | 75,203,217.72 |
| MHA(元) | 2,470,778.75 | 10,887,046.00 | - | 12,241,500.01 | - |
| MXN(元) | 1,424,352.01 | 5,840,352.87 | - | 8,792,325.53 | - |
| 抗病毒系列产品(元) | 5,029,778.78 | 37,106,725.78 | 8,085,486.73 | - | - |
| 糖尿病系列产品(元) | 37,615,383.53 | 121,126,501.79 | 94,451,427.08 | - | - |
| 新材料系列产品(元) | 15,917,767.75 | 61,852,830.76 | 30,217,881.89 | - | - |
| MPS(元) | - | 6,212,389.38 | - | - | - |
| 其他产品及服务(元) | 10,631,753.10 | 43,087,462.74 | 12,740,914.59 | - | - |
| 营业成本(元) | |||||
| MAH01(元) | - | - | - | 107,443,127.52 | 49,183,352.31 |
| MAH02(元) | - | - | - | 38,437,462.08 | 25,625,958.91 |
| CDMO及其他(元) | - | - | - | 111,053,981.18 | 55,040,693.64 |
| MHA(元) | 2,453,996.21 | 9,995,042.72 | - | 11,344,158.26 | - |
| MXN(元) | 1,440,255.95 | 5,728,043.90 | - | 8,766,369.23 | - |
| 抗病毒系列产品(元) | 7,318,900.00 | 22,298,000.44 | 4,870,544.27 | - | - |
| 糖尿病系列产品(元) | 36,101,877.78 | 83,151,452.16 | 64,382,262.48 | - | - |
| 新材料系列产品(元) | 21,140,045.46 | 60,152,629.32 | 28,179,158.73 | - | - |
| MPS(元) | - | 6,212,389.38 | - | - | - |
| 其他产品及服务(元) | 6,425,787.47 | 35,387,477.78 | 11,139,437.73 | - | - |
| 毛利(元) | |||||
| MAH01(元) | - | - | - | 17,522,150.96 | 5,486,968.09 |
| MAH02(元) | - | - | - | 37,644,617.50 | 23,593,288.82 |
| CDMO及其他(元) | - | - | - | 38,775,377.56 | 20,162,524.08 |
| MHA(元) | 16,782.54 | 892,003.28 | - | 897,341.75 | - |
| MXN(元) | -15,903.94 | 112,308.97 | - | 25,956.30 | - |
| 抗病毒系列产品(元) | -2,289,121.22 | 14,808,725.34 | 3,214,942.46 | - | - |
| 糖尿病系列产品(元) | 1,513,505.75 | 37,975,049.63 | 30,069,164.60 | - | - |
| 新材料系列产品(元) | -5,222,277.71 | 1,700,201.44 | 2,038,723.16 | - | - |
| MPS(元) | - | - | - | - | - |
| 其他产品及服务(元) | 4,205,965.63 | 7,699,984.96 | 1,601,476.86 | - | - |
| 毛利率(%) | |||||
| MAH01(%) | - | - | - | 14.02 | 10.04 |
| MAH02(%) | - | - | - | 49.48 | 47.94 |
| CDMO及其他(%) | - | - | - | 25.88 | 26.81 |
| MHA(%) | 0.68 | 8.19 | - | 7.33 | - |
| MXN(%) | -1.12 | 1.92 | - | 0.30 | - |
| 抗病毒系列产品(%) | -45.51 | 39.91 | 39.76 | - | - |
| 糖尿病系列产品(%) | 4.02 | 31.35 | 31.84 | - | - |
| 新材料系列产品(%) | -32.81 | 2.75 | 6.75 | - | - |
| MPS(%) | - | - | - | - | - |
| 其他产品及服务(%) | 39.56 | 17.87 | 12.57 | - | - |
| 收入构成(%) | |||||
| MAH01(%) | - | - | - | 33.60 | 30.53 |
| MAH02(%) | - | - | - | 20.46 | 27.48 |
| CDMO及其他(%) | - | - | - | 40.29 | 41.99 |
| MHA(%) | 3.38 | 3.81 | - | 3.29 | - |
| MXN(%) | 1.95 | 2.04 | - | 2.36 | - |
| 抗病毒系列产品(%) | 6.88 | 12.97 | 5.56 | - | - |
| 糖尿病系列产品(%) | 51.46 | 42.34 | 64.92 | - | - |
| 新材料系列产品(%) | 21.78 | 21.62 | 20.77 | - | - |
| MPS(%) | - | 2.17 | - | - | - |
| 其他产品及服务(%) | 14.55 | 15.06 | 8.76 | - | - |
| 毛利构成(%) | |||||
| MAH01(%) | - | - | - | 18.47 | 11.14 |
| MAH02(%) | - | - | - | 39.68 | 47.91 |
| CDMO及其他(%) | - | - | - | 40.87 | 40.95 |
| MHA(%) | - | 1.41 | - | 0.95 | - |
| MXN(%) | - | 0.18 | - | 0.03 | - |
| 抗病毒系列产品(%) | - | 23.44 | 8.71 | - | - |
| 糖尿病系列产品(%) | - | 60.10 | 81.43 | - | - |
| 新材料系列产品(%) | - | 2.69 | 5.52 | - | - |
| MPS(%) | - | 0.00 | - | - | - |
| 其他产品及服务(%) | - | 12.19 | 4.34 | - | - |